Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours

British Journal of Cancer

Volumn 103, Issue 9, 2010, Pages 1380-1390

  White, D E ^a   Burchill, S A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

ASK1; death receptors; Ewing's sarcoma family of tumours; fenretinide; p38 MAPK; TRAIL

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CASPASE 8; DACTINOMYCIN; DEATH RECEPTOR; ETOPOSIDE; FAS LIGAND; FENRETINIDE; MITOGEN ACTIVATED PROTEIN KINASE 14; NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; EWING SARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

CELL DEATH; CELL LINE, TUMOR; FENRETINIDE; HUMANS; MAP KINASE KINASE KINASE 5; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, DEATH DOMAIN; SARCOMA, EWING'S; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 77958610760     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605896     Document Type: Article

References (52)

1. Appierto V, Tiberio P, Villani MG, Cavadini E, Formelli F (2009) PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 30: 824-831
2. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7: 1001-1012
3. Brownhill SC, Taylor C, Burchill SA (2007) Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 96: 1914-1923
4. Chen JJ, Chou CW, Chang YF, Chen CC (2008) Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J Immunol 180: 8030-8039
5. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15: 369-379
6. Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S (2004) N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 11: 527-541
7. Das A, Banik NL, Ray SK (2008) N-(4-Hydroxyphenyl) retinamide induced both differentiation and apoptosis in human glioblastoma T98G and U87 MG cells. Brain Res 1227: 207-215
8. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966
9. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7: 813-820
10. Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S (2008) Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol 62: 655-665
11. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, Formelli F (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039
12. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death. Br J Haematol 130: 501-510
13. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL (2000) Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 20: 205-212
14. Hail Jr N, Kim HJ, Lotan R (2006) Mechanisms of fenretinide-induced apoptosis. Apoptosis 11: 1677-1694
15. Hemmings C (2010) The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology 42: 105-112
16. Hetschko H, Voss V, Seifert V, Prehn JH, Kogel D (2008) Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J 275: 1925-1936
17. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP (2008) Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580-595
18. Khwaja FS, Quann EJ, Pattabiraman N, Wynne S, Djakiew D (2008) Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 7: 3539-3545
19. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R (2006) N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25: 2785-2794
20. Kontny U (2006) Regulation of apoptosis and proliferation in Ewing's sarcoma\-opportunities for targeted therapy. Hematol Oncol 24: 14-21
21. Kouhara J, Yoshida T, Nakata S, Horinaka M, Wakada M, Ueda Y, Yamagishi H, Sakai T (2007) Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int J Oncol 30: 679-687
22. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A (2005) BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. Journal of Biological Chemistry 280: 19472-19479
23. Kwon D, Choi K, Choi C, Benveniste EN (2008) Hydrogen peroxide enhances TRAIL-induced cell death through up-regulation of DR5 in human astrocytic cells. Biochem Biophys Res Commun 372: 870-874
24. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, Koutelia N, Fisch P, Romero ME, Long L, Noellke P, Mackall CL, Niemeyer CM, Kontny U (2007) Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 170: 1917-1930
25. Lu G, Punj V, Chaudhary PM (2008) Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 7: 603-608
26. Maeda T, Hao C, Tron VA (2001) Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes. J Cutan Med Surg 5: 294-298
27. Mendoza FJ, Ishdorj G, Hu X, Gibson SB (2008) Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 13: 756-770
28. Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, Tsokos M, Kontny HU, Mackall CL (2004) Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 64: 8349-8356
29. Myatt SS, Redfern CP, Burchill SA (2005) p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin Cancer Res 11: 3136-3148
30. Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y (2007) The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 31: 803-811
31. Ng CP, Zisman A, Bonavida B (2002) Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53: 286-299
32. Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T, Sugimoto T (2004) Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblas-toma cells. Int J Cancer 112: 219-224
33. Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Redini F (2010) Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res 16: 2363-2374
34. Proctor A, Brownhill SC, Burchill SA (2009) The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility. Biochim Biophys Acta 1792: 260-274
35. Quann EJ, Khwaja F, Djakiew D (2007) The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res 67: 11402-11410
36. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107: 2250-2256
37. Shetty S, Gladden JB, Henson ES, Hu X, Villanueva J, Haney N, Gibson SB (2002) Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 7: 413-420
38. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ (2009) Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 54: 307-310
39. Song JH, Kandasamy K, Kraft AS (2008) ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 283: 25003-25013
40. 0s sarcoma cells. J Cancer Res Clin Oncol 133: 847-858
41. Su RY, Chi KH, Huang DY, Tai MH, Lin WW (2008) 15-deoxy-Delta12, 14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol Cancer Ther 7: 3429-3440
42. Thomadaki H, Floros KV, Scorilas A (2009) Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann N Y Acad Sci 1171: 276-283
43. Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC (2008) P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced syner-gistic anti-tumour potential in colon cancer cells. Oncogene 27: 4161-4171
44. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430
45. Westwood G, Dibling BC, Cuthbert-Heavens D, Burchill SA (2002) Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene 21: 809-824
46. White DE, Burchill SA (2008) BAY 11-7082 induces cell death through NF-kappaB-independent mechanisms in the Ewing's sarcoma family of tumours. Cancer Lett 268: 212-224
47. Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA (2004) Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75NTR. J Biol Chem 279: 47912-47928
48. Woo IS, Eun SY, Jang HS, Kang ES, Kim GH, Kim HJ, Lee JH, Chang KC, Kim JH, Han CW, Seo HG (2009) Identification of ADP-ribosylation factor 4 as a suppressor of N-(4-hydroxyphenyl)retinamide-induced cell death. Cancer Lett 276: 53-60
49. Woo SH, Park IC, Park MJ, An S, Lee HC, Jin HO, Park SA, Cho H, Lee SJ, Gwak HS, Hong YJ, Hong SI, Rhee CH (2004) Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upre-gulation of CD95/Fas by NF-kappaB activation. Int J Cancer 112: 596-606
50. Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279: 45495-45502
51. Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB (2009) Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res 69: 6581-6589
52. Yoshida S, Narita T, Koshida S, Ohta S, Takeuchi Y (2003) TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines. Pediatr Res 54: 709-717